Finnish nanonization specialists Nanoform have filed for GMP certification with the Finnish Medicines Agency (FIMEA), the company said. In December 2018, Nanoform announced construction of a new GMP manufacturing facility in Helsinki. The company, which recently won the the 2019 Excellence in Pharma: Formulation award at CPhI, plans to offer GMP clinical manufacturing of APIs.
Nanoform Head of Manufacturing David Rowe commented, “Filing for GMP status with FIMEA is a key milestone in Nanoform’s history. We look forward to working with our partners to deliver enhanced APIs to clinical trials and to help provide patients with faster access to innovative new treatments.”
Chief Technology Officer Niklas Sandler said, “We are delighted to end this exceptional year with our application for GMP clinical manufacture certification. By expanding our manufacturing capability, we are on course to increase the number of partners who benefit from our best-in-class nanoparticle engineering technology.”
Read the Nanoform press release.
